[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558984":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":47,"centralContacts":51,"locations":57,"responsibleParty":74,"collaborators":42,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":42,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":42,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":42,"overallStatus":60,"whyStopped":42,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","EXPERIMENTAL","ZG005 10 mg\u002Fkg administered intravenously every 3 weeks (Q3w) + Bevacizumab (Avastin®) 15 mg\u002Fkg administered intravenously Q3w",[13,14],"Biological: ZG005 for Injection","Biological: Bevacizumab",{"label":16,"type":10,"description":17,"interventionNames":18},"Group B","ZG005 20 mg\u002Fkg administered intravenously Q3w + Bevacizumab (Avastin®) 15 mg\u002Fkg administered intravenously Q3w",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Group C","Sintilimab 200 mg administered intravenously Q3w + Bevacizumab (达攸同®) 15 mg\u002Fkg administered intravenously Q3w",[23,14],"Biological: Sintilimab",[25,32,38,43],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"BIOLOGICAL","ZG005 for Injection","10 mg\u002Fkg or 20 mg\u002Fkg administered intravenously Q3w",[9,16],[31],"ZG005",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Bevacizumab","15 mg\u002Fkg administered intravenously Q3w",[9,16],[37],"Avastin",{"type":26,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Sintilimab","200 mg administered intravenously Q3w",[20],null,{"type":26,"name":33,"description":34,"armGroupLabels":44,"otherNames":45},[20],[46],"达攸同",[48],{"name":49,"affiliation":5,"role":50},"Jason Wu","STUDY_CHAIR",[52],{"name":53,"role":54,"phone":55,"phoneExt":42,"email":56},"Bo Liu","CONTACT","+86-021-5838-2983","liub@zelgen.com",[58],{"facility":59,"status":60,"city":61,"state":62,"zip":42,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"West China Hospital of Sichuan University","RECRUITING","Chengdu","Sichuan","China","CN",{"type":66,"coordinates":67},"Point",[68,69],104.06667,30.66667,{"lat":69,"lon":68},[72],{"name":73,"role":54,"phone":42,"phoneExt":42,"email":42},"Hong Wu",{"type":75,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100558984","phase-2-study-of-zg005-combined-with-bevacizumab-versus-sintilimab-combined-with-bevacizumab-in-advanced-hepatocellular-carcinoma-100558984",false,"NCT06558227","Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Fully understand the study and voluntarily sign the informed consent form.\n* 18-75 years of age;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；\n* Life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n* Patients were deemed unsuitable for participating in the study by the investigator for any reasons.","ALL","18 Years","75 Years",{"count":87,"type":88},90,"ESTIMATED","INTERVENTIONAL",[91],"PHASE2","This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.",[94],"Hepatocellular Carcinoma","2024-12-11",{"date":97,"type":98},"2024-12-16","ACTUAL",{"date":100,"type":98},"2024-10-24",{"date":102,"type":88},"2026-10",{"name":5,"class":6},1]